Immunotherapy combo aims to wipe out High-Risk rectal cancer before surgery
NCT ID NCT07214142
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation can better shrink or eliminate tumors in people with locally advanced rectal cancer that has a high chance of coming back. About 30 participants will receive the combination treatment before surgery. The main goal is to see how many patients have no cancer cells left in their tissue after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1 inhibitor (immunotherapy drug) combined with chemotherapy and radiation
What this could lead to
If successful, this combination could increase the chance of eliminating all tumor cells before surgery, potentially reducing recurrence risk for high-risk rectal cancer patients.
What could go wrong
This is a small, early-phase (Phase 2) single-arm study with only 30 participants, so results may not apply broadly. Immunotherapy can cause immune-related side effects, and the added benefit over standard treatment is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••